drugset / Trial / NCT00202995
Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS
RandomizedParallel-groupOpen-labelPrevention
Summary
Randomized study designed to look at the difference in relapse rates between patients remaining on their current interferon medication and those switched to Copaxone®
Timeline
- Start
- 2004-07
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glatiramer Acetate | Small molecule | 20 mg | Subcutaneous |
| Comparator | Interferon beta-1a | Protein / enzyme biologic | 44 ug | — |
| Comparator | Interferon beta-1b | Protein / enzyme biologic | 250 mg | — |